Similar Efficacy and Safety of Basaglar ® and Lantus ® in Patients with Type 2 Diabetes in Age Groups ( & lt; 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

ConclusionsLY IGlar and SA IGlar exhibit similar efficacy and safety in patients with T2D who are ≥ 65 years and in those< 65 years.Trial RegistrationClinicalTrials.gov trial registration: NCT01421459.FundingEli Lilly and Company and Boehringer-Ingelheim.

http://link.springer.com/10.1007/s13300-018-0405-5

Source: Diabetes Therapy - March 14, 2018 Category: Endocrinology Source Type: research